- ABOUT JIPO
- TRADE MARKS
- GEOGRAPHICAL INDICATIONS
- TRADITIONAL KNOWLEDGE
Intellectual Property Watch
Original news and analysis on international IP policy
Updated: 13 min 23 sec ago
Today, the annual World Health Assembly is poised to approve a new plan on research and development into medical products that are affordable to all. NGOs, industry and other observers welcomed the outcome.
As the 69th World Health Assembly draws to a close, member states are being asked to approve a series of draft global health sector strategies for HIV, viral hepatitis, and sexually transmitted infections. And the issues involve some questions of intellectual property rights.
A closed-door drafting group this evening arrived seemingly easily at agreement on a resolution on broadening work on new ways to fund research and development into medical products, according to participants. The agreement includes the creation of a new expert committee on health R&D, and asks for a WHO proposal on a pooled fund, they said. [Update: draft text now available]
Reform of the WHO, support for the Contingency Fund for Emergency to enable swift initial responses by the WHO, and a special R&D and innovation chapter in the G7 Ise-Shima Vision for Global Health that does not include the word intellectual property are some of the notables after the G7 Summit closed today in Japan. Counting pages, Global Health and lessons from the recent Ebola and Zika outbreaks did receive the biggest attention. But the G7 would not be its old usual without considerable warnings and some concrete proposals how to fight global terrorism and violent extremism.
Two years after Ebola, the World Health Organization continues to push forward with a thorough overhaul of how it responds to health emergencies. These include Public Health Emergencies of International Concern (PHEICs), such as the Ebola and Zika outbreaks, as well as natural diseases, conflicts, refugee crises, and the like.
If adopted as expected tomorrow by the World Health Assembly, a framework guiding the relationships between the World Health Organization and outside actors will be the first of its kind in the United Nations system, according to sources.
Medicines for Europe, representing the generic, biosimilar, and medicines in Europe, announced today during a side event at the World Health Assembly, that it joined the Global Campaign to Fight Fake Medicines.
With the end of the annual World Health Assembly looming tomorrow, member states are working away behind closed doors to finalise a resolution on how the World Health Organization shall work with outside actors going forward.
The European Union trade secrets directive passed its final hurdle on 27 May when EU governments backed compromise text approved by the European Parliament on 14 April. Once the law has been formally published, member states will have up to two years to incorporate its provisions into domestic law.
According to a new report, by 2050, some 10 million lives could be lost a year due to antimicrobial resistance. This is an issue which has been central to this year’s World Health Assembly, and is of global consequence. Delegates gathered for the occasion noted a report by the World Health Organization secretariat on the global action plan on antimicrobial resistance adopted last year and options to develop a global stewardship framework to try to limit the use of antibiotics and develop new ones.
A side event to the World Health Assembly organised by a number of delegations on antibiotic research and innovation reflected the deep global concern about antimicrobial resistance and the lack of candidates to replace what was once considered as a miracle of modern medicine.
Public health advocates - and many nations - had high hopes that this year's World Health Assembly could finally agree on some alternative ways to fund research and development that leads to affordable medical products by de-linking R&D costs from prices, through the long-awaited discussion of a landmark 2012 report of a WHO expert group on medical R&D. This week, that discussion has spread across the highest profile topics of the week such as antimicrobial resistance and emergencies, but some are concerned that the public health safeguards recommended by the expert group may be being left behind.
Adopted five years ago, the World Health Organization Pandemic Influenza Preparedness (PIP) Framework is currently undergoing its first review. Member states gathered in committee at the World Health Assembly yesterday mostly expressed support for the framework, and took note of a report by the WHO secretariat.
At a side event to this week's World Health Assembly, GlaxoSmithKline detailed measures taken by the company to dispel the perception of conflict of interest, and build trust, including amending the ways its sales forces operate, and no longer paying speakers at scientific congresses, and said it wants to provide leadership on the issue. Patients and physicians associations call for mainstreaming those practices.
Eight ministerial meetings have prepared a fat stack of paper, the “sherpas” have nearly concluded their work, and civil society once more has passed its own resolution on how they propose to tackle the most daunting global problems. Now it's time for the G7 leaders' roundtables – and the photo ops in Ise-Shima, Japan. For two days, the heads of state of Canada, France, Germany, Italy, Japan, the United Kingdom and the United States will talk on trade, foreign policy, climate change and energy. And maybe some digital, R&D and intellectual property issues.
The 28 European Union member governments are preparing to request the European Commission to conduct an in-depth evaluation of the availability and affordability of EU medicinal products that could lead to changes in R&D and pricing models. An apparent first-of-its-kind, the assessment would look at market and data exclusivity, supplementary protection certificates, and intellectual property issues, according to an alleged copy of the draft Council conclusions obtained by Intellectual Property Watch.
The European Commission today unveiled a raft of strategies aimed at boosting the European Digital Single Market (DSM). Among them, the EC rejected the idea of imposing one-size-fits-all rules on online platforms but said it will consider sector-specific regulation to address specific problems relating to such platforms, including in the area of copyright.
In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Tim Wilsdon, Vice President, CRA.
At a side event to this week’s annual World Health Assembly, a member of the Netherlands Ministry of Health delivered an unexpected speech on access to medicines, calling for more clarity in the setting of medicine prices, looking inside and outside of the patent system for solutions, and praising de-linkage. Other panellists viewed partnerships as a key ingredient to fill research and development gaps. And a representative from the Gates Foundation advised against a hasty switch to new system.
The World Health Organization secretariat this week reported to its member states on progress made in implementing sweeping programmatic, governance, and management reforms. The report? WHO has made progress, but there is still a long way to go. Member states, meanwhile, used the opportunity to express concern about the way it is going.